Stromal CD4+ and CD8+ T Cells in Human Breast Carcinomas. Its Correlation with Chemokine MIG/CXCL9

Graciela Laguens, Silvia Coronato, Jorge Chambó, Vanda Di Girolamo

Cátedra de Patología B, Cátedra de Inmunología, Facultad de Medicina de la Universidad Nacional de La Plata, Buenos Aires, Argentina.

DOI: 10.4236/abcr.2012.12002                

Abstract

The interaction between some chemokines with tumoral and stromal cells can influence tumor progression. CXCL9, a monokine induced by interferon gamma (MIG), targets lymphocytes.The aim of our study was to identify and quantify CD4+ and CD8+ T cells in the stroma of human breast cancer and correlate them with the presence of MIG/CXCL9. In 58 specimens of human breast carcinoma and 10 normal breast tissue from mammoplasty surgery, immunohistochemistry and ELISA methods were performed. The number of CD4+ and CD8+ T cells in breast cancer tissue was significantly increased compared with normal breast tissue with a clear predominance of CD8+ T cells. MIG/CXCL9 levels were significantly elevated respect normal breast tissue. This chemokine correlated with the number of CD8+ T cells only in non-metastatic tumors. These data suggest that MIG targets cytotoxic T cells. Their recruitment into breast carcinoma can play a critical role in malignant progression, inhibiting the production of metastasis.

Keywords

Breast Cancer; CD4+ T cells; CD8+ T Cells’ MIG/CXCL9; Chemokines

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	J. B. Reome, J. C. Hylind, R. W. Dutton and M. J. Dobrzanski, “Type 1 and Type 2 Tumor Infiltrating Effector Cell Subpopulations in Progressive Breast Cancer,” Clinical Immunology, Vol. 111, No. 1, 2004, pp. 69-81.
[2]	D. G. De Nardo and L. M. Coussens, “Balancing Immune Response: Crosstalk between Adaptative and Innate Immune Cells during Breast Cancer Progression,” Breast Cancer Research, Vol. 9, No. 4, 2007, pp. 212-222.
[3]	A. Ben-Baruch, “The Multifaceted Roles of Chemokines in Malignancy,” Cancer and Metastasis Reviews, Vol. 25, No. 3, 2006, pp. 357-371.
[4]	D. Raman, P. J. Baugher, Y. M. Thu and A. Richmond, “Role of Chemokines in Tumor Growth,” Cancer Letters, Vol. 256, No. 2, 2007, pp. 137-165.
[5]	T. Tanaka, Z. Bai, Y. Srinoulprasert, B. G. Yang, H. Hayasaka and M. Miyasaka, “Chemokines in Tumor Progression and Metastasis,” Cancer Science, Vol. 96, No. 6, 2008, pp. 317-322. doi:10.1111/j.1349-7006.2005.00059.x
[6]	M. L. Balestrieri, A. Balestrieri, F. P. Mancini and C. Napoli, “Understanding the Immunoangiostatic CXC Chemokine Network,” Cardiovascular Research, Vol. 78, No. 2, 2008, pp. 250-256.
[7]	J. R. Groon and A. D. Luster, “CXC3 Ligand: Redundant, Collaborative and Antagonistic Functios,” Immunology and Cell Biology, Vol. 89, 2011, pp. 207-215. doi:10.1038/icb.2010.158
[8]	A. E. Karnoub and R. Weinberg, “Chemokine Networks and Breast Cancer Metastasis,” Breast Disease, Vol. 26, No. 3-4, 2007, pp. 75-85.
[9]	J. Vandercappellen, J. Van Damme and S. Struyf, “The Role of CXC Chemokines and Their Receptors in Cancer,” Cancer Letters, Vol. 267, No. 2, 2008, pp. 226-244.
[10]	P. Allavena, G. Germano, F. Marchesi and A. Mantovani, “Chemokines in Cancer Related Inflammation,” Experimental Cell Research, Vol. 317, No. 5, 2011, pp. 664- 667.
[11]	A. Mantovani, B. Savino, M. Locati, L. Zammataro, P. Allavena and R. Bonecchi, “The Chemokine System in Cancer Biology and Therapy,” Cytokine & Growth Factor Review, Vol. 21, No. 1, 2010, pp. 27-39.
[12]	A. Ben-Baruch, “Pro-Malignancy and Putative Antimalignancy Chemokines in the Regulation of Breast Cancer Progression,” In: F. Columbus, Ed., Focus on Immunology Research, Nova Science Publishers, New York, 2006, pp. 1-46.
[13]	T. C. Walser, S. Rifat, X. Ma, N. Kundu, C. Ward, O. Goloubeva et al., “Antagonism of CXCR3 Inhibits Lung Metastasis in a Murine Model of Metastatic Breast Cancer,” Cancer Research, Vol. 66, No. 15, 2006, pp. 7701- 7707. doi:10.1158/0008-5472.CAN-06-0709
[14]	T. Walser, X. Ma, N. Kundu, R. Dorsey, O. Goloubeba, A. M. Fulton, “Immune Mediated Modulation of Breast Cancer Growth and Metastasis by the Chemokine Mig (CXCL9) in a Murine model,” Immunother, Vol. 30, No. 5, 2007, pp. 490-497.
[15]	J. Valdivia-Silva, J. Franco-Barraza, A. Esparza Silva, G. Du Pont, G. Soldevila, I. Meza, et al., “Effect of Pro-In- flammatory Cytokine Stimulation on Human Breast Cancer: Implications of Chemokine Receptor Expression in Cancer Metastasis,” Cancer Letters, Vol. 283, No. 2, 2009, pp. 176-185.
[16]	T. F. Gajewski, Y. Meng, C. Blank, et al., “Immune Resistance Orchestrated by the Tumor Microenvironment,” Immunological Reviews, Vol. 213, No. 1, 2006, pp. 131- 145.
[17]	H. Harlin, Y. Meng, A. C. Peterson, et al., “Chemokine Expression in Melanoma Metastases Associated with CD8 + T-Cell Recruitment,” Cancer Research, Vol. 69, No. 3, 2009, pp. 3077-3085.
[18]	H. Ohtani, Z. Jin, S. Takegawa, T. Nakayama and O. Yoshie, “Abundant Expression of CXCL9 (MIG) by Stromal Cells That Include Dendritic Cells and Accumulation of CXCR3+ T Cells in Lymphocyte-Rich Gastric Carcinoma,” The Journal of Pathology, Vol. 217, No. 1, 2009, pp. 21-31.
[19]	H. Ohtani and O. Yoshie, “Morphometric Analysis of the Balance between CXCR3+ T Cells and FOXP3+ Regulatory T Cells in Lymphocyte-Rich and Conventional Gastric Cancers,” Virchows Arch, Vol. 456, No. 6, 2010, pp. 615-623.
[20]	A. Fulton, F. Miller, A. Weise and W. Z. Wei, “Prospects of Controlling Breast Cancer Metastasis by Immune Intervention,” Breast Disease, Vol. 26, 2007, pp. 115-127.
[21]	T. Kondo, H. Nakazawa, F. Ito, Y. Hashimoto, Y. Osaka, K. Futatsushama, et al., “Favorable Prognosis of Renal Cell Carcinoma with Increased Expression of Chemokines Associated with a Th1-Type Immune Response,” Cancer Science, Vol. 97, 2006, pp. 780-786. doi:10.1111/j.1349-7006.2006.00231.x
[22]	W. Di Girolamo, S. Coronato, E. Portiansky and G. Laguens, “Profile of Immune Cells in Lymph Nodes Draining Human Malignant Tumors,” Medicina, Vol. 68, 2008, pp. 423-427.
[23]	S. Hirano, Y. Iwashita, A. Sasaki, S. Kai, M. Ohta and S. Kitano, “Increased mRNA Expression of Chemokines in Hepatocellular Carcinoma with Tumor-Infiltrating Lymphocytes,” Journal of Gastroenterology and Hepatology, Vol. 22, No. 5, 2007, pp. 611-612.
[24]	J. Yu, “Targeting Chemokines as a Therapeutic Option for Hepatocellular Carcinoma: A Reality or Just a Fantasy?” Journal of Gastroenterology and Hepatology, Vol. 22, 2007, pp. 611-612. doi:10.1111/j.1440-1746.2007.04970.x
[25]	P. P. Leong, R. Mohammad, N. Ibrahim, H. Ithnin, M. Abdullah, W. C. Davis, et al., “Phenotyping of Lymphocytes Expressing Regulatory and Effector Markers in Infiltrating Ductal Carcinoma of the Breast,” Immunology Letters, Vol. 102, No. 2, 2006, pp. 229-236. doi:10.1016/j.imlet.2005.09.006